Yujian Ye

Dr. Yujian Ye


Research Focus & Metrics

Academic Career Length

3Years (2024-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
29 July 2024 in Phytomedicine
Verified
Journal Article
Closed access
YLYishan Lv
Yishan Lv
LYLiu Yang
Liu Yang
ZMZian Mao
Zian Mao
MZMingyuan Zhou
Mingyuan Zhou
BZBingqi Zhu
Bingqi Zhu
YYYujian Ye
Yujian Ye

3 February 2025 in International Journal of Biological Macromolecules
Verified
Journal Article
Closed access
FZFangmei Zhou
Fangmei Zhou
YGYing Guo
Ying Guo
WLWenxuan Li
Wenxuan Li
YHYiwen Hu
Yiwen Hu
LYLiu Yang
Liu Yang
ZDZhishan Ding
Zhishan Ding

2 July 2026 in Phytomedicine
Verified
Journal Article
Closed access
YHYiwen Hu
Yiwen Hu
WLWenxuan Li
Wenxuan Li
XHXiaorong Hu
Xiaorong Hu
MYMenghan Yang
Menghan Yang
BZBingqi Zhu
Bingqi Zhu
YYYujian Ye
Yujian Ye

26 June 2026 in Medicine
Verified
Journal Article
Open access
ZYZhubiao Ye
Zhubiao Ye
LMLi-tian Ma
Li-tian Ma
SWSu Wang
Su Wang
SZShuna Zhang
Shuna Zhang
YYYujian Ye
Yujian Ye
Rationale: Papulonecrotic tuberculid (PNT) and Poncet’s disease (PD) are rare, immune-mediated reactions to Mycobacterium tuberculosis (MTB) that occur without direct bacterial isolation. The concurrent manifestation of both conditions in a single individual is exceptionally rare, with only limited cases documented in the literature. This report documents a singular case of concurrent PNT and PD, illustrating multisystem delayed-type hypersensitivity as an exceptional manifestation of MTB. Patient concerns: A 30-year-old male presented with a 3-year history of recurrent, symmetrical necrotic papules on the extremities and trunk, evolving through sequential stages from papule to central necrosis, crusting, and varioliform scarring. He also reported episodes of inflammatory polyarthritis involving the knees, elbows, wrists, and metacarpophalangeal joints. He had sustained household contact with a grandmother diagnosed with pulmonary tuberculosis. Diagnoses: Laboratory testing revealed elevated total immunoglobulin E (>2000 IU/mL), an increased erythrocyte sedimentation rate (ESR = 31 mm/h), and elevated C-reactive protein (CRP = 29 mg/L). Tuberculin skin testing was positive (13 mm × 13 mm), and interferon-gamma release assay was positive. Skin biopsy revealed leukocytoclastic vasculitis, epithelioid necrotizing granulomas, and multinucleated giant cells. He was diagnosed with PNT and PD as hypersensitivity reactions to latent MTB infection. Interventions: Standard antitubercular therapy (isoniazid, rifampicin, and ethambutol) was administered. Outcomes: Complete resolution of cutaneous and articular symptoms was achieved within the 6-month follow-up period. Lessons: Concurrent PNT and PD underscore the potential of MTB to trigger synchronous multisystem immune reactions. The observed elevated immunoglobulin E levels suggest a possible T helper 2-skewed immunologic background, broadening the understanding of tuberculous hypersensitivity syndromes. In tuberculosis-endemic areas, clinicians should maintain a high index of suspicion for such atypical presentations to avoid diagnostic delays and prevent chronicity. Anti-MTB therapy remains the definitive and effective treatment for these immune-mediated phenotypes.

1 January 2026 in Clinical, Cosmetic and Investigational Dermatology
Verified
Journal Article
Open access
PDF file
BXBo Xie
Bo Xie
XZXiaoyan Zhang
Xiaoyan Zhang
XLXinxin Lei
Xinxin Lei
YZYuting Zhang
Yuting Zhang
QZQin Zhang
Qin Zhang
YYYujian Ye
Yujian Ye
Acquired reactive perforating collagenosis (ARPC) is a rare perforating dermatosis linked to systemic diseases, with unclear pathogenesis and no standardized therapy. We report a 53-year-old male with ARPC who failed conventional treatments but improved rapidly with upadacitinib 15 mg/day for one month, followed by 15 mg every other day. After three months, most lesions resolved, leaving hyperpigmentation and scars. Literature review shows conflicting reports: one case of ARPC improved with upadacitinib, another developed ARPC during upadacitinib treatment for atopic dermatitis. Our findings suggest upadacitinib may be effective for ARPC, especially in pruritic patients, regardless of diabetes status.

1 February 2026 in Clinical, Cosmetic and Investigational Dermatology
Verified
Journal Article
Open access
XZXiaoyan Zhang
Xiaoyan Zhang
MZMengyan Zhu
Mengyan Zhu
YYYujian Ye
Yujian Ye
Chronic spontaneous urticaria (CSU) is a refractory dermatosis characterized by recurrent wheals and pruritus. Although omalizumab is recommended for patients failing antihistamine therapy, some patients remain unresponsive. Tofacitinib is an oral JAK inhibitor that exerts immunosuppressive effects by blocking the key intracellular inflammatory signaling pathway (JAK-STAT). Currently approved for the treatment of rheumatoid arthritis, psoriatic arthritis, ulcerative colitis, and other conditions, it is also widely used in clinical practice for atopic dermatitis, vitiligo, and refractory chronic urticaria. Thus, tofacitinib may offer a novel therapeutic option for such patients. This retrospective study enrolled 10 CSU patients with suboptimal response to omalizumab who received tofacitinib (5 mg bid) for 24 weeks. Primary outcome was the proportion of patients achieving UCT (Urticaria Control Test) ≥ 12 at 12 weeks. Secondary outcomes included UAS7 (Urticaria Activity Score over 7 days) and UCT scores, along with safety events.Furthermore, through the review of medical records from the abovementioned 10 patients, it was found that all patients had completed blood routine, liver function, thyroid function, total IgE, antinuclear antibody, and coagulation tests prior to the initiation of this study’s treatment, or had undergone the same tests within the previous three months. After treatment began, the clinicians re-evaluated the above indicators within 3 to 6 months based on the patients’ specific conditions. The median UAS7 score decreased significantly from baseline 21 points to a nadir of 0 points at week 8, maintaining a median of 7 points at week 24. 57.1% of patients remained in remission. The median UCT score increased from 6.5 points at baseline to 12 points at week 8, with continued improvement through week 24. Mild adverse reactions occurred in 3 patients (2 upper respiratory tract infections, 1 abnormal liver function), with no serious adverse events. Tofacitinib shows potential in treating CSU patients with inadequate response to omalizumab, offering significant early symptom improvement in some cases with manageable safety. Larger randomized controlled trials are needed for further validation.